It isn’t but time to surrender on these corporations.
One nice technique to earn returns above the market common is to determine shares which can be underperforming regardless of basic value will increase, however have the potential to ultimately get well. There are numerous candidates to select from because the inventory market finishes out the 12 months on a robust notice.
Two battered shares value contemplating in 2026 are Viking Therapeutics (VKTX 3.13%) and Zoetis (ZTS +0.34%). Each of those healthcare-focused corporations went within the incorrect route in 2025, however issues might change considerably over the subsequent 12 months.
Picture supply: Getty Photographs.
1.Viking Therapeutics
Initially, let’s maintain one factor in thoughts. Viking Therapeutics is a clinical-stage biotechnology firm, and so they are typically no less than barely extra dangerous than common. Lots can go incorrect for a corporation whose inventory value falls. However for these with elevated danger urge for food, there might be vital upside potential right here. Viking is not like most drug corporations earlier than they turn into worthwhile. Sturdy outcomes had been achieved in Part 2 for candidates in weight administration, the business’s hottest therapy space.
The corporate’s VK2735 is an investigational GLP-1 anti-obesity drug at the moment in Part 3 trials. And subsequent 12 months, Viking Therapeutics might launch information from this medical trial. There is a good likelihood it’s going to achieve success and Viking’s inventory value will skyrocket primarily based on interim outcomes. Moreover, the biotech firm is creating an oral formulation of VK2735.
In the present day’s modifications
(-3.13%) -$1.14
present value
$35.32
Key information factors
Market capitalization
4 billion {dollars}
day by day vary
$35.21 – $36.66
52 week vary
$18.92 – $43.55
quantity
16K
common quantity
3.8M
That is why Viking Therapeutics is transferring ahead with these applications that would ultimately faucet into the burgeoning weight-loss drug market and create blockbuster merchandise. Viking inventory has moved within the incorrect route this 12 months for no less than two causes. First, some buyers determined to money out their earnings because of robust inventory costs in 2024. Second, the interim outcomes of oral VK2735 had been compromised by a excessive charge of affected person dropout because of extreme unwanted side effects.
In my opinion, I believe Viking Therapeutics can handle this situation, particularly for the reason that efficacy of oral VK2735 on this research was robust. Though the very best dose of the drug triggered probably the most unwanted side effects, decrease doses had been additionally thought-about commercially viable. So Viking’s very promising property in weight administration might result in a rebound as early as subsequent 12 months because of robust medical and regulatory advances. That is why right this moment’s inventory value is value contemplating.
2. Zoetis
Zoetis is a number one veterinary pharmaceutical firm with an enormous product portfolio. The corporate’s efforts within the companion animal sector are its most essential development driver.
However this 12 months, two of the corporate’s medicine confronted severe issues. Librera and Sorrencia are indicated for the therapy of osteoarthritis (OA) ache in canine and cats, respectively. There have been studies of significant unwanted side effects, and each are the topic of ongoing regulatory investigation. These developments are having an influence on Zoetis’ monetary outcomes and inventory value.
Even with this problem remaining, is it doable for shares to get well in 2026? My view is that it’s doable. Zoetis enters 2025 dealing with elevated competitors inside its most essential dermatology franchise, notably for Apoquel, a therapy for allergic itch in canine. Zoetis has successfully addressed that risk, and dermatology stays a key development driver for the corporate.
In the present day’s modifications
(0.34%) $0.43
present value
$126.41
Key information factors
Market capitalization
$56 billion
day by day vary
$125.45 – $127.60
52 week vary
$115.25 – $177.40
quantity
672
common quantity
4.8M
gross revenue
70.29%
dividend yield
1.58%
Moreover, with thousands and thousands of canine untreated or undertreated, we consider Zoetis nonetheless has vital room for development and ample alternative to extend gross sales. Moreover, new approvals, notably in areas which were difficult for the corporate in 2025, might assist flip the tide. Zoetis introduced the approval of Lenivia for OA ache in canine in Canada and Europe.
The benefit of Lenivia over Librara is that it’s a longer-acting drug, which reduces the variety of visits to the veterinarian. Portela, a long-acting analog of Lenivia for OA ache in cats, additionally received approval in Europe. Each might achieve momentum subsequent 12 months, serving to Zoetis overcome latest points and sending a shockwave by way of the inventory.
However even when that does not occur in 2026, Zoetis is a superb long-term choice. The corporate is a frontrunner within the animal well being business, has confirmed modern capabilities and a wealthy portfolio, generates steady revenues, and will increase dividends at a gentle tempo. The corporate’s dividend has elevated 458% over the previous 10 years.
